Mirsaidi Niely, Burns Matthew P, McClain Steve A, Forsyth Edward, Li Jonathan, Dukes Brittany, Lin David, Nahvi Roxanna, Giraldo Jheison, Patton Megan, Wang Ping, Lin Ke, Miller Edmund, Ratliff Timothy, Hamidi Sayyed, Crist Scott, Takemaru Ken-Ichi, Szema Anthony
Department of Technology and Society, College of Engineering and Applied Sciences, Stony Brook University, Stony Brook, NY, United States.
Three Village Allergy & Asthma, PLLC, South Setauket, NY, United States.
Front Endocrinol (Lausanne). 2017 Aug 7;8:162. doi: 10.3389/fendo.2017.00162. eCollection 2017.
To identify if the absence of the vasoactive intestinal peptide (VIP) gene enhances susceptibility to death from metastatic bladder cancer, two strains of mice were injected with MB49 murine bladder cancer cells. The growth and spread of the cancer was measured over a period of 4 weeks in C57BL/6 mice and 5 weeks in VIP knockout (KO) mice. A Kaplan-Meier plot was constructed to compare control C57BL/6 mice and C57BL/6 mice with MB49 vs. VIP KO controls and VIP KO mice with MB49. The wild-type (WT) strain (C57BL/6) contained the VIP gene, while the other strain, VIP knockout backcrossed to C57BL/6 (VIP KO) did not and was thus unable to endogenously produce VIP. VIP KO mice had increased mortality compared to C57BL/6 mice at 4 weeks. The number of ulcers between both groups was not statistically significant. studies indicated that the presence VIP in high doses reduced MB49 cell growth, as well as macrophage inhibitory factor (MIF), a growth factor in bladder cancer cells. These findings support the concept that VIP may attenuate susceptibility to death from bladder cancer, and that it exerts its effect via downregulation of MIF.
为了确定血管活性肠肽(VIP)基因缺失是否会增加转移性膀胱癌导致死亡的易感性,给两株小鼠注射了MB49小鼠膀胱癌细胞。在C57BL/6小鼠中对癌症的生长和扩散进行了4周的测量,在VIP基因敲除(KO)小鼠中进行了5周的测量。构建了Kaplan-Meier曲线,以比较对照C57BL/6小鼠和接种MB49的C57BL/6小鼠与VIP KO对照和接种MB49的VIP KO小鼠。野生型(WT)品系(C57BL/6)含有VIP基因,而另一个品系,即回交至C57BL/6的VIP基因敲除小鼠(VIP KO)则不含有该基因,因此无法内源性产生VIP。在4周时,VIP KO小鼠的死亡率高于C57BL/6小鼠。两组之间溃疡的数量没有统计学意义。研究表明,高剂量的VIP可降低MB49细胞的生长,以及巨噬细胞抑制因子(MIF),后者是膀胱癌细胞中的一种生长因子。这些发现支持了VIP可能会降低膀胱癌导致死亡的易感性这一概念,并且它通过下调MIF发挥其作用。